Phoenix, AZNCT05416307Now EnrollingIRB Ready

Secondary Hemophagocytic Lymphohistiocytosis Clinical Trial in Phoenix, AZ

Access cutting-edge secondary hemophagocytic lymphohistiocytosis treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.

Sponsored by Electra Therapeutics Inc.

Quick Self-Assessment

See if you qualify for this Phoenix location

Preparing your pre-screening questions...

Expert Care in Phoenix

Access secondary hemophagocytic lymphohistiocytosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related secondary hemophagocytic lymphohistiocytosis treatment provided free

Apply for This Phoenix Location

Check if you qualify for this secondary hemophagocytic lymphohistiocytosis clinical trial in Phoenix, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Phoenix

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Phoenix site if eligible
  4. 4Begin participation

About This Secondary Hemophagocytic Lymphohistiocytosis Study in Phoenix

Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T

Sponsor: Electra Therapeutics Inc.

Who Can Participate

Inclusion Criteria

for Part 1: 1. ≥12 years at the time of HLH diagnosis (Cohort 1). 2. ≥6 years at the time of HLH diagnosis (Cohort 2-3). 3. Treatment naïve or relapsed/refractory (Cohorts 1 and 2). 4. Treatment naïve or early refractory (Cohort 3). 5. Participant with sHLH confirmed criteria based on fulfilling 5 out of 8 HLH-2004 diagnostic criteria. Key Inclusion Criteria for Part 2: 1. Cohort A: Adults with treatment-naïve, malignancy-associated sHLH. 2. Cohort B: Adults with treatment-naïve, non-malignancy-associated sHLH. 3. Cohort B: Adults with treatment-naïve, malignancy-associated sHLH, diagnosed by OHI index. 4. Cohort B: 13 to 17 years olds with treatment-naïve sHLH. 5. Cohort B: 6 to 12 year olds, with refractory sHLH (safety lead-in cohort). 6. Cohort B: 6 to 12 year olds, with treatment-naïve sHLH (after completion of safety lead-in cohort). Key

Exclusion Criteria

for Part 1: 1. Known or previous treatment for primary HLH 2. Any other significant concurrent, un

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT05416307) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Secondary Hemophagocytic Lymphohistiocytosis Treatment Options in Phoenix, AZ

If you're searching for secondary hemophagocytic lymphohistiocytosis treatment options in Phoenix, AZ, this clinical trial (NCT05416307) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced secondary hemophagocytic lymphohistiocytosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all secondary hemophagocytic lymphohistiocytosis clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Hypertension Trials in Phoenix, AZ

See all pulmonary hypertension clinical trials recruiting in Phoenix — not just this study.

Browse Pulmonary Hypertension Trials in Phoenix →

Browse More Trials by Condition

Pulmonary Hypertension TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Phoenix?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Phoenix, AZ